- Home
- MESO vs PRGS Comparison
MESO vs PRGS Comparison
Compare MESO & PRGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MESO | PRGS |
|---|---|---|
| Founded | 2004 | 1981 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | N/A | 1991 |
Fundamental Metrics
Financial Performance| Metric | MESO | PRGS |
|---|---|---|
| Price | $18.65 | $42.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $24.00 | ★ $67.00 |
| AVG Volume (30 Days) | 218.4K | ★ 502.8K |
| Earning Date | 02-25-2026 | 01-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.09 |
| Revenue | $17,198,000.00 | ★ $940,126,000.00 |
| Revenue This Year | $576.59 | $32.42 |
| Revenue Next Year | $41.15 | $1.44 |
| P/E Ratio | ★ N/A | $37.98 |
| Revenue Growth | ★ 191.39 | 31.41 |
| 52 Week Low | $9.61 | $39.00 |
| 52 Week High | $21.00 | $65.60 |
Technical Indicators
Market Signals| Indicator | MESO | PRGS |
|---|---|---|
| Relative Strength Index (RSI) | 56.49 | 48.10 |
| Support Level | $17.90 | $39.60 |
| Resistance Level | $18.73 | $43.96 |
| Average True Range (ATR) | 0.51 | 1.16 |
| MACD | -0.14 | -0.21 |
| Stochastic Oscillator | 43.00 | 61.41 |
Price Performance
Historical ComparisonAbout MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
About PRGS Progress Software Corporation (DE)
Progress Software Corporation provides software operate in one operating segment: software products for the development, deployment, and management of responsible, AI-powered applications and digital experiences. Following are products: Chef, Corticon, Data Direct, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, WhatsUp Gold. Geographical regions include United States, Canada, EMEA, Latin America, and Asia Pacific.